Exploratory analysis of biological age measures in a remyelination clinical trial.

ABSTRACT: Enhancing CNS myelin repair (remyelination) is a promising strategy to prevent neurodegeneration and associated progressive disability in multiple sclerosis. Remyelination becomes inefficient with older chronological age, but the relationship between measures of biological age and remyelination has not been previously described in a clinical cohort. Here, we investigated two measures of biological age amongst participants of the Cambridge Centre for Myelin Repair One trial of bexarotene: MRI brain age (BA_MRI) and a blood-based biological age (BA_Blood). In people with radiologically stable multiple sclerosis (n = 44 of 49 total participants), we found that treatment with bexarotene, along with promoting remyelination, was associated with significant decrease in

SUBMITTER: McMurran CE 

PROVIDER: S-EPMC11852336 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature